Recursion Pharmaceuticals, Inc. (RXRX) Misses Q4 EPS by 12c

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported Q4 EPS of ($0.53), $0.12 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $4.55 million versus the consensus estimate of $13.4 million.

For earnings history and earnings-related data on Recursion Pharmaceuticals, Inc. (RXRX) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Increasing unusual put option volume: LION GPN FJET BTG PURR JCI AVGX KBH VTRS
• Comstock Metals to open solar recycling facility in Cambridge, Ohio